Article Text

Download PDFPDF

Rheumatic disease and COVID-19
Free
  1. Jean W Liew1,
  2. Elizabeth R Graef2
  1. 1Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington, USA
  2. 2Department of Rheumatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
  1. Correspondence to Dr Jean W Liew, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA 98195, USA; liew.jw{at}gmail.com

Statistics from Altmetric.com

We appreciated the letter from Monti et al, which was the first dedicated report of patients with rheumatic disease who have been diagnosed with COVID-19.1 We have also reviewed the response from Joob and Wiwanitkit,2 which unfortunately perpetuates the notion that individuals with systemic lupus erythematosus (SLE) or other rheumatic disease may be protected from COVID-19 infection via hydroxychloroquine use. Although the origins of this claim are not entirely clear, they may arise from the fact that rheumatic or autoimmune diseases were not initially reported among other comorbidities in the first large Chinese case series.3–5 Some of …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.